According to a study comprising 90 ICI-treated patients with advanced NSCLC, those with high LAG3 and low-PD-L1 expression showed markedly lower PFS relative to the low LAG3 and high-PD-L1 expression groups (56). The gene discussed is LAG3; the disease is non-small cell lung carcinoma.